Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.
Epistemonikos ID: f2b08427ee077e2fddbb70ed0cc9801b5b460f9e
First added on: Jun 14, 2024